SG11201406093VA - An h3 receptor antagonist for use in the treatment of alzheimer's disease - Google Patents

An h3 receptor antagonist for use in the treatment of alzheimer's disease

Info

Publication number
SG11201406093VA
SG11201406093VA SG11201406093VA SG11201406093VA SG11201406093VA SG 11201406093V A SG11201406093V A SG 11201406093VA SG 11201406093V A SG11201406093V A SG 11201406093VA SG 11201406093V A SG11201406093V A SG 11201406093VA SG 11201406093V A SG11201406093V A SG 11201406093VA
Authority
SG
Singapore
Prior art keywords
alzheimer
disease
treatment
receptor antagonist
antagonist
Prior art date
Application number
SG11201406093VA
Inventor
Pascal Barneoud
Véronique Blanchard-Bregeon
Philippe Delay-Goyet
Véronique Mary
Jean Menager
Grancha Mathilde Lopez
Thomas Rooney
Nathalie Schussler
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201406093VA publication Critical patent/SG11201406093VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG11201406093VA 2012-04-06 2013-04-05 An h3 receptor antagonist for use in the treatment of alzheimer's disease SG11201406093VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305415.7A EP2647377A1 (en) 2012-04-06 2012-04-06 Use of an h3 receptor antagonist for the treatment of alzheimer's disease
US201361792635P 2013-03-15 2013-03-15
PCT/EP2013/057241 WO2013150150A1 (en) 2012-04-06 2013-04-05 An h3 receptor antagonist for use in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
SG11201406093VA true SG11201406093VA (en) 2014-10-30

Family

ID=46001073

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201406093VA SG11201406093VA (en) 2012-04-06 2013-04-05 An h3 receptor antagonist for use in the treatment of alzheimer's disease
SG10201801200PA SG10201801200PA (en) 2012-04-06 2013-04-05 An h3 receptor antagonist for use in the treatment of alzheimer's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201801200PA SG10201801200PA (en) 2012-04-06 2013-04-05 An h3 receptor antagonist for use in the treatment of alzheimer's disease

Country Status (17)

Country Link
US (2) US20150031893A1 (en)
EP (2) EP2647377A1 (en)
JP (1) JP6143842B2 (en)
KR (1) KR20150000490A (en)
CN (1) CN104363911A (en)
AR (1) AR090605A1 (en)
AU (1) AU2013244928B2 (en)
BR (1) BR112014024736A2 (en)
CA (1) CA2868481A1 (en)
ES (1) ES2618924T3 (en)
MX (1) MX354020B (en)
PL (1) PL2833887T3 (en)
RU (1) RU2014144615A (en)
SG (2) SG11201406093VA (en)
TW (1) TW201402119A (en)
UY (1) UY34734A (en)
WO (1) WO2013150150A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
CN105764510A (en) * 2013-09-09 2016-07-13 赛诺菲 An H3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
CN114053289B (en) * 2020-08-06 2023-06-27 北京箭牧科技有限公司 Application of adefovir in preparing medicine for preventing and treating nervous system degenerative diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
JP2006512404A (en) 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Aryloxyalkylamine derivatives as H3 receptor ligands
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
CA2509413C (en) 2002-12-20 2012-05-01 Glaxo Group Limited Benzazepine derivatives for the treatment of neurological disorders
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
DK1615909T3 (en) 2003-04-23 2008-11-17 Glaxo Group Ltd Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders
ATE370135T1 (en) 2003-07-18 2007-09-15 Glaxo Group Ltd SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
PT1751111E (en) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (en) 2004-05-25 2006-08-04 Sanofi Synthelabo TETRAHYDROISOQUINOLYLSULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
WO2005123723A1 (en) 2004-06-18 2005-12-29 Glaxo Group Limited 3-cycloalkylbenzazepines as histamine h3 antagonists
GB0418267D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
ATE387202T1 (en) 2004-10-15 2008-03-15 Glaxo Group Ltd PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTOR LIGANDS
KR20070091007A (en) 2004-12-07 2007-09-06 글락소 그룹 리미티드 Indenyl derivatives and use thereof for the treatment of neurological disorders
EP1858900B1 (en) 2005-03-14 2009-01-07 Glaxo Group Limited Fused thiazole derivatives having affinity for the histamine h3 receptor
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
EP1790646A1 (en) 2005-11-24 2007-05-30 Sanofi-Aventis Isoquinoline und benzo[h]isoquinoline derivatives, their preparation and their therapeutical application as antagonists of histamine H3 receptor .
US20100120747A1 (en) 2006-06-23 2010-05-13 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
CL2008000597A1 (en) 2007-03-01 2008-09-05 Glaxo Group Ltd DOSAGE FORM INCLUDING 6- (3-CYCLLOBUTIL-2,3,4,5-TETRAHYDRO-1H-BENZO [D] AZEPIN-7-IL OXI) -N-METHYL NICOTINAMIDE, A STABILIZER AND A EXCIPIENT; PREPARATION PROCEDURE; AND ITS USE TO TREAT NEUROLOGICAL DISEASES.
US20090170869A1 (en) 2007-09-06 2009-07-02 Desmond John Best Piperazine derivative having affinity for the histamine h3 receptor
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010023170A1 (en) 2008-08-29 2010-03-04 Glaxo Group Limited Dosage form comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine or a salt thereof
WO2010026113A1 (en) * 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
CA2766154C (en) 2009-06-26 2015-04-07 Beverly C. Langevin Novel fumarate salts of a histamine h3 receptor antagonist
AR077859A1 (en) 2009-08-12 2011-09-28 Boehringer Ingelheim Int COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
WO2011051423A1 (en) 2009-11-02 2011-05-05 Glaxo Group Limited Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
FR2976286B1 (en) 2011-06-08 2013-05-24 Servier Lab 4- {3- [TRANS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} BENZAMIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
EP2745876A1 (en) 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
CN105764510A (en) * 2013-09-09 2016-07-13 赛诺菲 An H3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Also Published As

Publication number Publication date
SG10201801200PA (en) 2018-04-27
TW201402119A (en) 2014-01-16
MX354020B (en) 2018-02-08
US20150031893A1 (en) 2015-01-29
JP6143842B2 (en) 2017-06-07
US9789102B2 (en) 2017-10-17
JP2015516963A (en) 2015-06-18
RU2014144615A (en) 2016-05-27
EP2833887A1 (en) 2015-02-11
CN104363911A (en) 2015-02-18
EP2647377A1 (en) 2013-10-09
KR20150000490A (en) 2015-01-02
EP2833887B1 (en) 2016-12-28
BR112014024736A2 (en) 2017-07-11
UY34734A (en) 2013-11-29
AU2013244928B2 (en) 2017-08-10
AU2013244928A1 (en) 2014-10-30
CA2868481A1 (en) 2013-10-10
ES2618924T3 (en) 2017-06-22
MX2014011992A (en) 2015-05-08
US20160101099A1 (en) 2016-04-14
WO2013150150A1 (en) 2013-10-10
PL2833887T3 (en) 2017-06-30
AR090605A1 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
HRP20182069T1 (en) Pharmaceutical compositions for treating alzheimer's disease
IL269511A (en) New therapeutic approaches for treating parkinson's disease
HUE056006T2 (en) Combination for the treatment of parkinson's disease
EP2911664A4 (en) Combination therapies for the treatment of alzheimer's disease and related disorders
PL3119911T3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
HUS2000020I1 (en) Ciclesonide for the treatment of airway disease in horses
EP2978446A4 (en) Methods and agents for treating alzheimer's disease
IL230441A0 (en) Diagnosis of alzheimer's disease
IL233572B (en) Fixed dose combination therapy of parkinson's disease
EP2676665A4 (en) Use of -mangostin in preparation of medicaments for treating alzheimer's disease
EP2906225A4 (en) Methods of treating kennedy's disease
EP2667896A4 (en) Methods and compositions for treating alzheimer's disease
EP2829605A4 (en) Method for screening therapeutic and/or prophylactic agents for alzheimer's disease
SG10201801200PA (en) An h3 receptor antagonist for use in the treatment of alzheimer's disease
IL234412B (en) Iloperidone metabolite for use in the treatment of psychiatric disorders
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
FR2989088B1 (en) RADIOTRACER FOR ALZHEIMER'S DISEASE